Antioxidant use in Friedreich ataxia

Journal of the Neurological Sciences

Volumn 267, Issue 1-2, 2008, Pages 174-176

  Myers, Lauren ^a   Farmer, Jennifer M ^a,b   Wilson, Robert B ^b   Friedman, Lisa ^a   Tsou, Amy ^a   Perlman, Susan L ^c   Subramony, Sub H ^d   Gomez, Christopher M ^e   Ashizawa, Tetsuo ^f   Wilmot, George R ^g   Mathews, Katherine D ^h   Balcer, Laura J ^a   Lynch, David R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF IOWA   (United States)

Author keywords

Ataxia; Cerebellum; Clinical trial; Idebenone

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMANTADINE; BACLOFEN; BUSPIRONE; GABAPENTIN; IDEBENONE; SELENIUM; UBIDECARENONE;

ADOLESCENT; ADULT; ARTICLE; CARDIOMYOPATHY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FRIEDREICH ATAXIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREDICTION; PRIORITY JOURNAL; SCOLIOSIS; SIDE EFFECT; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; ANTIOXIDANTS; CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUGS, NON-PRESCRIPTION; FEMALE; FRIEDREICH ATAXIA; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; PATIENT SELECTION; PLACEBO EFFECT; SELF MEDICATION; TRINUCLEOTIDE REPEAT EXPANSION; UBIQUINONE;

EID: 39149111563     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.10.008     Document Type: Article

References (15)

1. Lynch D.R., Farmer J.M., Balcer L.J., and Wilson R.B. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 59 (2002) 743-747
2. Cossee M., Durr A., Schmitt M., Dahl N., Trouillas P., Allinson P., et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45 (1999) 200-206
3. O'Neill H.A., Gakh O., Park S., Cui J., Mooney S.M., Sampson M., et al. Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry 44 (2005) 537-545
4. Seznec H., Simon D., Bouton C., Reutenauer L., Hertzog A., Golik P., et al. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet 14 (2005) 463-474
5. Stehling O., Elsasser H.P., Bruckel B., Muhlenhoff U., and Lill R. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet 13 (2004) 3007-3015
6. Lodi R., Hart P.E., Rajagopalan B., Taylor D.J., Crilley J.G., Bradley J.L., et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 49 (2001) 590-596
7. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., and DiDonato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60 (2003) 1676-1679
8. Lynch D.R., Farmer J.M., Tsou A.Y., Perlman S., Subramony S.H., Gomez C.M., et al. Clinical measures in Friedreich ataxia: comparison of examination and performance measures. Neurology 66 (2006) 1711-1776
9. Rustin P., von Kleist-Retzow J.C., Chantrel-Groussard K., Sidi D., Munnich A., and Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354 (1999) 477-479
10. Buyse G., Mertens L., Di Salvo G., Matthijs I., Weidemann F., Eyskens B., et al. Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60 (2003) 1679-1681
11. Rotig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17 (1997) 215-217
12. Kemper K., Gardiner P., and Woods C. Changes in use of herbs and dietary supplements (HDS) among clinicians enrolled in an online curriculum. BMC Complement Altern Med 7 (2007) 21
13. Azaz-Livshits T., Muszkat M., and Levy M. Use of complementary alternative medicine in patients admitted to internal medicine wards. Int J Clin Pharmacol Ther 40 (2002) 539-547
14. Kelly J.P., Kaufman D.W., Kelley K., Rosenberg L., and Mitchell A.A. Use of herbal/natural supplements according to racial/ethnic group. J Altern Complement Med 12 (2006) 551-561
15. Kishiyama S.S., Marjorie, Leahy M.J., Zitzelberger T.A., Guariglia R., Zajdel D.P., et al. Patterns of dietary supplement usage in demographically diverse older people. Altern Ther Health Med 11 (2005) 48-53